Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Prometheus Biosciences, Inc. (RXDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2023 |
4
| Hendrix Martin (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,071 shares
@ $0
Disposed/sold 40,000 options to buy
@ $22.48, valued at
$899.2k
Disposed/sold 20,500 options to buy
@ $29.02, valued at
$594.9k
|
|
| 06/16/2023 |
4
| Laur James (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,071 shares
@ $0
Disposed/sold 40,000 options to buy
@ $22.48, valued at
$899.2k
Disposed/sold 20,500 options to buy
@ $29.02, valued at
$594.9k
|
|
| 06/16/2023 |
4
| Stenhouse Mark (COO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 12,754 shares
@ $0
Disposed/sold 14,000 shares
@ $0
Disposed/sold 40,000 options to buy
@ $0.5, valued at
$20k
Disposed/sold 240,000 options to buy
@ $6.7, valued at
$1.6M
Disposed/sold 70,371 options to buy
@ $36.32, valued at
$2.6M
Disposed/sold 86,582 options to buy
@ $29.56, valued at
$2.6M
Disposed/sold 34,085 options to buy
@ $110.2, valued at
$3.8M
|
|
| 06/16/2023 |
4
| Szela Mary T (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,071 shares
@ $0
Disposed/sold 40,000 options to buy
@ $19, valued at
$760k
Disposed/sold 20,500 options to buy
@ $29.02, valued at
$594.9k
|
|
| 06/16/2023 |
4
| McKenna Mark C. (Chairman, President and CEO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 178,098 shares
@ $0
Disposed/sold 161,105 options to buy
@ $2.9, valued at
$467.2k
Disposed/sold 132,741 options to buy
@ $1.7, valued at
$225.7k
Disposed/sold 20,000 options to buy
@ $3.1, valued at
$62k
Disposed/sold 481,725 options to buy
@ $3.7, valued at
$1.8M
Disposed/sold 566,307 options to buy
@ $6.7, valued at
$3.8M
Disposed/sold 290,000 options to buy
@ $36.32, valued at
$10.5M
Disposed/sold 246,639 options to buy
@ $29.56, valued at
$7.3M
Disposed/sold 128,930 options to buy
@ $110.2, valued at
$14.2M
|
|
| 06/16/2023 |
4
| Swain Judith L (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,071 shares
@ $0
Disposed/sold 30,000 options to buy
@ $6.7, valued at
$201k
Disposed/sold 20,500 options to buy
@ $29.02, valued at
$594.9k
|
|
| 06/16/2023 |
4
| PAPA JOSEPH C (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 7,278 shares
@ $0
Disposed/sold 10,000 shares
@ $0
Disposed/sold 15,000 options to buy
@ $3.1, valued at
$46.5k
Disposed/sold 27,340 options to buy
@ $3.7, valued at
$101.2k
Disposed/sold 22,652 options to buy
@ $6.7, valued at
$151.8k
Disposed/sold 2,165 options to buy
@ $36.32, valued at
$78.6k
Disposed/sold 22,551 options to buy
@ $29.02, valued at
$654.4k
|
|
| 06/16/2023 |
4
| Hassan Fred (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,123 shares
@ $0
Disposed/sold 40,000 options to buy
@ $16.82, valued at
$672.8k
Disposed/sold 541 options to buy
@ $36.32, valued at
$19.6k
Disposed/sold 21,013 options to buy
@ $29.02, valued at
$609.8k
|
|
| 06/16/2023 |
4
| Marshall Keith W (CFO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 87,973 shares
@ $0
Disposed/sold 52,838 options to buy
@ $3.1, valued at
$163.8k
Disposed/sold 93,040 options to buy
@ $3.7, valued at
$344.2k
Disposed/sold 135,913 options to buy
@ $6.7, valued at
$910.6k
Disposed/sold 102,155 options to buy
@ $36.32, valued at
$3.7M
Disposed/sold 86,582 options to buy
@ $29.56, valued at
$2.6M
Disposed/sold 34,085 options to buy
@ $110.2, valued at
$3.8M
Disposed/sold 12,920 options to buy
@ $108.76, valued at
$1.4M
|
|
| 06/16/2023 |
4
| Adams Helen C. (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed/sold 2,674 shares
@ $0
Disposed/sold 30,000 options to buy
@ $6.7, valued at
$201k
Disposed/sold 1,083 options to buy
@ $36.32, valued at
$39.3k
Disposed/sold 21,526 options to buy
@ $29.02, valued at
$624.7k
|
|
| 06/16/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/16/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/16/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/16/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 06/16/2023 |
8-K
| Resignation/termination of a director |
| 06/02/2023 |
4
| McKenna Mark C. (Chairman, President & CEO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Exercised 122,528 options to buy
@ $2.9, valued at
$355.3k
Exercised 3 options to buy
@ $1.7, valued at
$5.1 |
|
| 06/02/2023 |
4
| Marshall Keith W (CFO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Exercised 78,162 options to buy
@ $3.1, valued at
$242.3k
|
|
| 06/02/2023 |
4
| Stenhouse Mark (COO) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed of 14,000 shares
@ $0
Acquired 14,000 shares
@ $0 |
|
| 06/02/2023 |
4
| PAPA JOSEPH C (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Disposed of 10,000 shares
@ $0
Acquired 10,000 shares
@ $0 |
|
| 05/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/19/2023 |
4
| Szela Mary T (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,071 shares
@ $0 |
|
| 05/19/2023 |
4
| Swain Judith L (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,071 shares
@ $0 |
|
| 05/19/2023 |
4
| PAPA JOSEPH C (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,278 shares
@ $0 |
|
| 05/19/2023 |
4
| Laur James (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,071 shares
@ $0 |
|
| 05/19/2023 |
4
| Hendrix Martin (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,071 shares
@ $0 |
|
| 05/19/2023 |
4
| Hassan Fred (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,123 shares
@ $0 |
|
| 05/19/2023 |
4
| Adams Helen C. (Director) has filed a Form 4 on Prometheus Biosciences, Inc.|
Txns:
| Granted 2,174 shares
@ $0 |
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 9, 2023 -- Prometheus Biosciences, Inc. , a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximatel..." |
|
| 04/28/2023 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
8-K
| Quarterly results |
|
|
|